Attention Deficit-Hyperactivity Disorder Clinical Trial
— TLR;Official title:
Toll-Like Receptor Polymorphism, Antinuclear Antibodies and Beta-hemolytic Group A Streptococcus Infections in Attention-Deficit/Hyperactivity Disorder: an Observational Study
NCT number | NCT04038073 |
Other study ID # | ADHD_TLR |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 3, 2019 |
Est. completion date | December 1, 2020 |
The aim of this observational cross-sectional study is to evaluate the streptococcal infection (clinical history, ASLO title and anti-DNAse title B) and autoimmunity (ABGA antibodies) in a sample of 100 adult patients diagnosed with ADHD (ie in patients in whom the disorder is permanent). Another objective will be to evaluate the frequency and types of genetic alterations of innate immunity (TLR polymorphisms, MyD88, IRAK-4) that can determine an infantile susceptibility to gram positive infections (ie S. pyogenes, S. pneumoniae, S. aureus) and the possible relationship between these elements, also in relation to comorbidity with other ABGA-related pathologies, to identify a possible pathogenetic immune mechanism of ADHD. Prevalence data will be obtained on an outpatient ADHD population for previous (history) and recent streptococcal infection (ASLO and Anti-DNAsiB), for the detection of ABGA and for the co-presence of other ABGA-related pathologies. By comparing the subgroups obtained by dividing the results on the basis of the positive infectious history, anti-streptococcus, autoantibody and comorbidity titers, it will be possible to assess whether the elevation of the ABGA titer is only linked to the previous/current infection ("infectious" group) or if there is a subpopulation of ADHD patients presenting pathological elevation of ABGA titers in the absence of infectious pictures ("immune" group). Furthermore, it is expected that the comparison of the descriptive polymorphisms TLR, MyD88 and IRAK-4 between the "infectious" and "immune" group may show a predisposition in subjects of the "immune" group.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 1, 2020 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - diagnosis of ADHD according to DSM-5 criteria |
Country | Name | City | State |
---|---|---|---|
Italy | AOU San Luigi Gonzaga di Orbassano | Orbassano | Torino |
Lead Sponsor | Collaborator |
---|---|
University of Turin, Italy |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of Antistreptolysin O and Anti-Deoxyribonuclease B | diagnostic blood sample test to measure streptococcal infections | up to 1 year till the end of the study | |
Primary | Measurement of TLR, MyD88, IRAK-4 polymorphism | diagnostic blood sample test to measure genetic alterations of innate immunity | up to 1 year till the end of the study | |
Primary | Measurement of Anti-Basal Ganglia Antibody | diagnostic blood sample test to assess the autoimmune component | up to 1 year till the end of the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04152629 -
Real World Evidence of the Efficacy and Safety of FOQUEST
|
Phase 4 | |
Completed |
NCT03003286 -
Community Based Intervention for Children With ADHD and ASD
|
N/A | |
Completed |
NCT01831622 -
Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder
|
Phase 4 | |
Completed |
NCT03847402 -
The Early Integrated Intervention for Child Brain-developmental Disorders in China
|
N/A | |
Withdrawn |
NCT01769300 -
Improving the Medication Management of Patients With Attention-Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT03440346 -
Biomarker Research in ADHD: the Impact of Nutrition
|
N/A | |
Completed |
NCT04689282 -
Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT02778360 -
Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) in Attention-Deficit/Hyperactivity Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT04228094 -
Assesment of TDApp1 an eHelath Tool to Make Therapeutic Recommendations for Patients With ADHD
|